Genmab — December 2019
-
God morgen.
-
Dara, the new Bacon https://ash2019blogs.myeloma.org/dara-the-new-bacon-i-mean-beacon-of-myeloma/
-
-
-
Genmab i en nøddeskal:
"After all, when a company has a strong balance sheet, it can often find ways to invest in growth, even if it takes some time". -
Tak for link Solsen.
-
-
https://www.rigshospitalet.dk/presse-og-nyt/nyheder/nyheder/Sider/2019/december/computermodel-skal-nulstille-kraeftsygdom.aspx Interessant selv om det nok ikke Genmab relateret.
-
a bit more on teprotumumab https://www.fiercebiotech.com/biotech/a-unanimous-vote-fda-panel-greenlights-horizon-s-eye-drug-teprotumumab?utm_source=internal&utm_medium=rss https://www.healio.com/endocrinology/thyroid/news/online/{b02b4c4e-6f26-42bc-8267-74c2021b12dd}/fda-committee-unanimously-recommends-approval-of-teprotumumab-for-thyroid-eye-disease
-
this was from DNB, which we saw - Genmab (Hold, TP: DKK1685.00) - Encouraging first data on GEN3013
At the ASH conference in Orlando (7–10 December), the focus was on very strong data from J&J’s BCMA CAR-T, JNJ-4528, with 100% ORR and 69% CRR in highly pre-treated patients, which could pose a long-term risk to Darzalex. In addition, we find the early safety and efficacy data on CD3xCD20 (GEN3013) encouraging and have included it in our valuation. -
GMAB to be included in NASDAQ Biotechnology Index (Nasdaq:NBI) https://app.researchpool.com/company/ndaq-us6311031081-nasdaq/press/nasdaq-ndaq-annual-changes-to-the-nasdaq-biotechnology-index-1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind